ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

LEGN Legend Biotech Corporation

44.89
1.37 (3.15%)
27 Jun 2024 - Closed
Delayed by 15 minutes
Name Symbol Market Type
Legend Biotech Corporation NASDAQ:LEGN NASDAQ Depository Receipt
  Price Change % Change Price Bid Price Offer Price High Price Low Price Open Price Traded Last Trade
  1.37 3.15% 44.89 42.32 46.34 45.31 42.61 43.23 1,164,891 01:00:00

Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2023 Results

13/02/2024 1:00pm

Business Wire


Legend Biotech (NASDAQ:LEGN)
Historical Stock Chart


From Dec 2023 to Jun 2024

Click Here for more Legend Biotech Charts.

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing, and commercializing novel therapies to treat life-threatening diseases, will host a conference call for investors at 8:00 am ET on Monday, March 11, 2024, to review fourth-quarter and full-year 2023 results.

During the webcast and conference call, executive members will provide an overview of Legend Biotech’s performance for the quarter and the fiscal year.

Investors and other interested parties may join the live audio webcast of the call via this weblink.

A replay version of the webcast and earnings news release will be available through the Investor Relations section of Legend Biotech’s website under the Events and Presentation section approximately two hours after the call concludes.

ABOUT LEGEND BIOTECH

Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell (gd T) and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of cutting-edge therapeutics for patients worldwide.

Learn more at www.legendbiotech.com and follow us on X (formerly Twitter) and LinkedIn.

INVESTOR: Jessie Yeung Tel: (732) 956-8271 jessie.yeung@legendbiotech.com

PRESS: Alexandra Ventura Tel: (732) 850-5598 media@legendbiotech.com

1 Year Legend Biotech Chart

1 Year Legend Biotech Chart

1 Month Legend Biotech Chart

1 Month Legend Biotech Chart

Your Recent History

Delayed Upgrade Clock